Non-cardiovascular comorbidities in patients with chronic coronary syndromes (review) (2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes)

Сareful evaluation of patient history, including of anginal symptoms, and evaluation of risk factors and manifestation of coronary artery disease (CAD), as well as proper physical examination and basic testing, are crucial for the diagnosis and management of chronic coronary syndrome(s) (CCS) and non-cardiovascular comorbidities.

Anti-ischaemic treatment must be adapted to the individual patient based on comorbidites, co-administered therapies, expected tolerance and adherence, and patient preferences. The choice of anti-ischaemic drugs to treat chronic coronary sydromes should be adapted to the patient’s heart rate, blood pressure, and left-ventricular (LV) function.

In patients with active cancer treatment decisions should based on life be expectancy, additional comorbidities such as thrombocytopenia, increased thrombosis propensity. and potential interactions between drugs used in CCS management and antineoplastic agents.

In asymptomatic patients with diabetes mellitus, a periodic resting electrocardiogram is recommended for cardiovascular detection of conduction abnormalities, atrial fibrillation, and silent myocardial infarction.

Recommendations for chronic kidney disease (CRD): use iodinated contrast agents is minimized in patients with severe CKD and preserved urine production to prevent further deterioration.

It is recommended that particular attention is paid to side effects of drugs, intolerance, and overdosing in elderly patients with chronic coronary syndromes.

Hormone replacement therapy is not recommended for risk reduction in post- menopausal women. Тransmyocardial revascularization is not recommended in patients with debilitating angina refractory to optimal medical and revascularization strategies.

1. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano Ch. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi: 10.1093/eur-heartj/ehz425.

2. Lupanov V.P. New 2019 ESC Guidelines for Diagnosis and Management of Chronic Coronary Syndromes (review). Meditsinskiy sovet = Medical Council. 2020;(4):30-36. (In Russ.) doi: 10.21518/2079-701X-2020-4-30-36.

3. Darby S., McGale P, Peto R., Granath F., Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ. 2003;326:256-257. doi: 10.1136/bmj.326.7383.256.

4. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922-944. doi: 10.1097/HJH.0000000000001276.

5. Shepherd J., Barter P., Carmera R., Deedwania P., Fruchart J.C., Haffner S. et al. Effect of lowering LDLcholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220-1226. doi: 10.2337/dc05-2465.

6. Cosentino F., Grant PJ., Aboyans V., Bailey CJ., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal. 2020;41(2):255-323. doi: 10.1093/eur-heartj/ehz486.

7. Zinman B., Wanner C., Lachin J.M., Fittchet D., Bluhmki E., Hantel S. et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascularomes outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.

8. Neil B., Perkovic V., Matthews D.R., Mahaffey K.W., Fulcher G., Erondu N. et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(3):387-393. doi: 10.1111/dom.12829.

9. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi: 10.1056/nejmoa1611925.

10. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827.

11. Tregubenko E.V., Klimkin A.S. Peculiarities of the course of coronary heart disease in patients with diabetes mellitus 2 type. Trudnyy patsient = Difficult Patient. 2015;13(7):26-29. (In Russ.) Available at: http//t-pacient.ru/arti-cles/9040.

12. Hernandez A.F., Green J.B., Janmohamed S., D’Agostino R.B., Granger C.B., Jones N.P. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X.

13. Kang S.H., Park G.M., Lee S.W., Yun S.C., Kim Y.U., Cho Y.R. et al. Long-Term Prognostic Value of Coronary CT Angiography in Asymptomatic Type 2 Diabetes Mellitus. JACC Cardiovasc Imaging. 2016;9(11):1292-1300. doi: 10.1016/j.jcmg.2016.01.040.

14. Clerc O.F., Fuchs T.A., Stehli J., Benz D.C., Grani C., Messerli M. et al. On-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018;19(8):838-846. doi: 10.1093/ehjci/jey014.

15. Lee J.M., Kang J., Lee E., Hwang D., Rhee T.M., Park J. et al. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry. JACC Cardiovasc Interv. 2016;9(20):2097-2109. doi: 10.1016/j.jcin.2016.06.051.

16. Fox C.S., Matsushita K., Woodward M., BiLo HJ., Chalmers J., Heerspink HJ.L. et aL. Associations of kidney disease measures with mortality and end-stage renaL disease in individuals with and without diabetes: a meta-anaLysis. Lancet. 2012;380(9854):1662-1673. doi: 10.1016/S0140-6736(12)61350-6.

17. Palmer S.C., Navaneethan S.D., Craig J.C., Johnson D.W., Perkovic V., Hegbrant J., StrippoLi G.F. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2.

18. Kim E.S., Carrigan T.P, Menon V. Enrollment of women in National Heart, Lung, and BLood Institute-funded cardiovascular randomized controlled trials faiLs to meet current federaL mandates for incLusion. J Am Coll Cardiol. 2008;52(8):672-673. doi: 10.1016/j.jacc.2008.05.025.

19. Ricci B., Cenko E., VasiLjevic Z., Stankovic G., Kedev S., KaLpak O. et aL. Acute Coronary Syndrome: The Risk to Young Women. J Am Heart Assoc. 2017;6(12):e007519. doi: 10.1161/JAHA.117.007519.

20. Cenko E., Yoon J., Kedev S., Stankovic G., VasiLjevic Z., KrLjanac G. et aL. Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age. JAMA Intern Med. 2018;178(5):632-639. doi: 10.1001/jamainternmed.2018.0514.

21. OerteLt-Prigione S., SeeLand U., KendeL F., Rucke M., FLoeL A., Gaissmaier W. et aL. CardiovascuLar risk factor disrtibution and subjective risk estimation in urban women the BRFRI study: a randomized cross-sectionaL study. BMC Med. 2015;13:52. doi: 10.1186/s12916-015-0304-9.

22. Davis M., Diamond J., Montgomery D., Krishnan S., EagLe K., Jackson E. Acute coronary syndrome in young women under 55 years of age: cLinicaL characteristics, treatment, and outcomes. Clin Res Cardiol. 2015;104(8):648-655. doi: 10.1007/s00392-015-0827-2.

23. Briones E., LacaLLe J.R., Marin-Leon I., Rueda J.R. TransmyocardiaL Laser revascuLarization versus medicaL therapy for refractory angina. Cochrane Database Syst Rev. 2015;2015(2):CD003712. doi: 10.1002/14651858.CD003712.pub3.

24. Arora R.R., Chou T.M., Jain D., FLeishman B., Crawford L., McKierman T. et aL. Effects of enhanced externaL counterpuLsation on HeaLth-ReLated OuaLity of Life continue 12 months after treatment: a substudy of the MuLticenter Study of Enhanced ExternaL CounterpuLsation. J Investig Med. 2002;50(1):25-32. doi: 10.2310/6650.2002.33514.

25. Oganov R.G., Simanenkov V.I., BakuLin I.G., BakuLina N.V., Barbarash O.L., Boytsov S.A. et aL. Comorbidities in cLinicaL practice. ALgorithms for diagnostic and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi: 10.15829/1728-8800-2019-1-5-66.

26. Verheye S., JoLicoeur E.M., Behan M.W., Pettersson T., Sainsbury P., HiLL J. et aL. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372(6):519-527. doi: 10.1056/NEJMoa1402556.

27. Varenne O., Cook S., Sideris G., Kedev S., Guisset T., Carrie D. et aL. DrugeLuting stents in eLderLy patients with coronary artery disease (SENIOR): a randomised singLe-bLind triaL. Lancet. 2018;391(10115):41-50. doi: 10.1016/S0140-6736(17)32713-7.

28. Urban P, Meredith I.T., Abizaid A., Pocock SJ., Carrie D., Naber C. et aL. PoLymer-free Drug-Coated Coronary Stents in Patients at High BLeeding Risk. N Engl J Med. 2015;373(21):2038-2047. doi: 10.1056/NEJMoa1503943.

29. Zipes D.P, SvorkdaL N., Berman O., Boortz-Marx R., Henry T. et aL. SpinaL cord stimuLation therapy for patients with refractory angina who are not candidates for revascuLarization. Neuromodulation. 2012;15(6):550-559. doi: 10.1111/j.1525-1403.2012.00452.x.